

OY 301 LysSerLysTyrArgGlnAlaPheAsnAlaAlaValValHisHisMetArgLysLeu 320
DB 918 AACGCAAGTGGAGCCACGCTTCAACGCCAGCAGCTGTGGTGCACCATGAGGAAGCTA 977
OY 321 HisMetAsnLeuHisSerProGlyValArgProGluValGluAsnArgProProGluThr 340
DB 978 CACATGAACTTGCACAGCCCGGGGTCTCCACAGAGGTGGAGAACAGGCCCTGAAACCT 1037
OY 341 GlnAlaSerGluThrSerArgProSerProGluIleThrIleThrGluAlaProVal 360
DB 1038 CAAGCCTCAGAAACCTCTAGACCCAGCTCCCTCGATCATCATCACCGAGCCACCTGTC 1097
OY 361 LeuAspHisSerValAlaLeuProAlaLeuThrGlnLeuProCysGlnHisGlyArg 380
DB 1098 CTGGACACAGTAGCACTCCCTGGCTGACCCAAATTACCTGCCAGCATGGCCGCGG 1157
OY 381 ProThrAlaProGlyGlyArgSerLeuAsnCysLeuValAsnGlySerLeuHisIleSer 400
DB 1158 CCCACTGCCCTGTGGCAGTCCCTCACTGGCTGGTCAATGGTCCCTCCACATCAGC 1217
OY 401 SerSerLeuValProMetHisGlnGlySerLeuAlaAlaGlyProCysGlyCysSer 420
DB 1218 AGCAGCTGTGGCCCATCATCAGGGTCCCTGCGCGGGCCCTGTGGCTGCTGCTCC 1277
OY 421 SerCysLeuAsnIleGlySerLysGlyLysSerSerTyrCysSerGluProThrLeuLeu 440
DB 1278 AGCTGCTGAACATTGGGAGCAAGAAAGTCTCTCTCTAGAGCCACACTCCTC 1337
OY 441 LysAlaAsnLysLysGlnAsnPheLysSerGluValMetValProValLysAlaSer 460
DB 1338 AAAAGGCCCAACAAAAACAGAACTTCAAGTCGGAGGTGATGTTACAGTTAAAGCCAGT 1397
OY 461 GlySerSerHisCysArgAlaGlyGlnThrGlyValCysLeuIleMet 476
DB 1398 GGCAGCTCCCACTGCGGCGAGGCGAGCTGGAGTCTGTCTCATTTATG 1445

KW Human: nootropic; immunosuppressant; cyostatic; gene therapy; cancer;
 KW Peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW anyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia.
 XX
 OS Homo sapiens.
 XX
 XX WO200153312-A1.
 XX
 XX 26-JUL-2001.
 XX
 XX 26-DEC-2000; 2000WO-US34263.
 XX
 XX 21-JAN-2000; 2000US-0488725.
 XX
 XX 25-APR-2000; 2000US-0552317.
 XX
 XX 09-JUL-2000; 2000US-0598042.
 XX
 XX 19-JUL-2000; 2000US-0620312.
 XX
 XX 03-AUG-2000; 2000US-0653450.
 XX
 XX 14-SEP-2000; 2000US-0682191.
 XX
 XX 19-OCT-2000; 2000US-0693036.
 XX
 XX 29-NOV-2000; 2000US-0727344.
 XX
 XX (NYSE-) NYSEQ INC.
 XX
 XX Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren P, Wang D;
 XX Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 XX Zhao QA, Zhou P, Goodrich R, Drmanec RT;
 XX
 XX WPI; 2001-442253/47.
 XX
 XX N-PSDB; AAI60703.
 XX
 XX Novel nucleic acids and polypeptides, useful for treating disorders
 XX such as central nervous system injuries -
 XX
 XX Example 2; SEQ ID NO 6478; 10078pp; English.
 XX
 XX The invention relates to human nucleic acids (AAI57798-AAI61369) and
 XX the encoded polypeptides (AAI58642-AAI62213) with nootropic,
 XX immunosuppressant and cyostatic activity. The polynucleotides are useful
 XX in gene therapy. A composition containing a polypeptide or polynucleotide
 XX of the invention may be used to treat diseases of the peripheral nervous
 XX system, such as peripheral nervous injuries, peripheral neuropathy and
 XX localized neuropathies and central nervous system diseases, such as
 XX Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 XX lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 XX utilisation of the activities such as: immune system suppression,
 XX Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 XX and thrombolytic activity, cancer diagnosis and therapy, drug screening,
 XX assays for receptor activity, arthritis and inflammation, leukaemia and
 XX C.N.S disorders.
 XX Note: The sequence data for this patent did not form part of the printed
 XX specification.
 XX
 XX Sequence 497 AA;
 XX
 XX Query Match 100.0%; Score 2513; DB 22; Length 497;
 XX Best Local Similarity 100.0%; Pred. No. 5,1e-220;
 XX Matches 476; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 XX 1 MGRKEEDCCSWKKQTNIKRTIFMEVLGSGAFSEVFLVKQLTKLPALKCKIKKSPAF 60
 XX |
 XX 22 MGRKEEDCCSWKKQTNIKRTIFMEVLGSGAFSEVFLVKQLTKLPALKCKIKKSPAF 81
 XX |
 XX 61 RDSLENEIYAVLKKIKKENIVTLEDIVESTHYLYVQVSGGELFDRLERGVYTEKDA 120
 XX |
 XX 82 RDSLENEIYAVLKKIKKENIVTLEDIVESTHYLYVQVSGGELFDRLERGVYTEKDA 141
 XX |
 XX 121 SLVIOQVLSAVKYLKENGIVHRDKPENILLYTPENSKINITDFGLSKNEONGIMSTAC 180
 XX |
 XX 142 SLVIOQVLSAVKYLKENGIVHRDKPENILLYTPENSKINITDFGLSKNEONGIMSTAC 201
 XX |

RESULT 2
 ID AAI41547
 AC AAI41547
 DT 22-OCT-2001 (first entry)
 DE Human polypeptide SEQ ID NO 6478.
 XX

QY 181 GTPGYAPVLAQKPYSKAYDCWSIGVITILLCGYPPFYBETESKLFEKINEGYEFES 240
 DB 202 GTPGYAPVLAQKPYSKAYDCWSIGVITILLCGYPPFYBETESKLFEKINEGYEFES 261
 QY 241 PFNDIISAKDFTCHLEKOPNERITCEKALSHPWIDONTALHROIIPSYSLQIQKFA 300
 DB 262 PFNDIISAKDFTCHLEKOPNERITCEKALSHPWIDONTALHROIIPSYSLQIQKFA 321
 QY 301 KSKWROAFNAAVYVHMRKLHMLHSPGVRPEVENPPEPTQASETSPPSPPEITITBAPV 360
 DB 322 KSKWROAFNAAVYVHMRKLHMLHSPGVRPEVENPPEPTQASETSPPSPPEITITBAPV 381
 QY 361 LDHSAVALPALTQLPCOHGRPTAPGGRSLNCLVNGSLHISSSLVPHQGLAAGPCCCS 420
 DB 382 LDHSAVALPALTQLPCOHGRPTAPGGRSLNCLVNGSLHISSSLVPHQGLAAGPCCCS 441
 QY 421 SCLNIGSKGSSYCSPTLLKANKKONPKSEVAVPVKASGSSHCRAGOTGVCLIM 476
 DB 442 SCLNIGSKGSSYCSPTLLKANKKONPKSEVAVPVKASGSSHCRAGOTGVCLIM 497

OS Homo sapiens.
 XX
 PN WO200153312-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 26-DEC-2000; 2000WO-US34263.
 XX
 PR 21-JAN-2000; 2000US-0488725.
 PR 25-APR-2000; 2000US-0552317.
 PR 09-JUL-2000; 2000US-0398042.
 PR 19-JUL-2000; 2000US-0620312.
 PR 03-AUG-2000; 2000US-0653450.
 PR 14-SEP-2000; 2000US-0662191.
 PR 19-OCT-2000; 2000US-0851036.
 PR 29-NOV-2000; 2000US-0727344.
 XX
 PA (HYSE-) HYSEQ INC.
 XX
 PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren P, Wang D;
 PI Wang J, Wang Z, Mehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
 PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
 XX
 DR WPI: 2001-442253/47.
 DR P-PSDB: AAM41547.
 XX
 PT Novel nucleic acids and polypeptides, useful for treating disorders
 PT such as central nervous system injuries -
 XX
 PS Claim 1; SEQ ID NO 4692; 10078pp; English.
 XX
 CC The invention relates to human nucleic acids (AA157798-AA161369) and
 CC the encoded polypeptides (AA138642-AA142213) with neurotropic,
 CC immunosuppressant and cytostatic activity. The polynucleotides are useful
 CC in gene therapy. A composition containing a polypeptide or polynucleotide
 CC of the invention may be used to treat diseases of the peripheral nervous
 CC system, such as peripheral nervous injuries, peripheral neuropathy and
 CC localised neuropathies and central nervous system diseases, such as
 CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
 CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
 CC utilisation of the activities such as: Immune system suppression,
 CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, cancer diagnosis and therapy drug screening,
 CC assays for receptor activity, arthritis and inflammation, leukaemia and
 CC C.N.S disorders.
 CC Note: the sequence data for this patent did not form part of the printed
 CC specification.
 XX
 SO Sequence 1956 BP: 474 A: 559 C: 508 G: 414 T: 1 other:

Query Match 68.9%; Score 1687; DB 22; Length 1956;
 Best Local Similarity 99.9%; Pred. No. 0;
 Matches 1787; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY	12	CTCAAGCAGGATTTCTCCGAGTCCCTGGCATCTCTCAGAGCTTCAACTCTGGAGGCAAT	71
DB	7	CTCAGCAGGATTTCTCCGAGTCCCTGGCATCTCTCAGAGCTTCAACTCTGGAGGCAAT	66
QY	72	GGGTGGAAGGAGGAGATGACTGGAGTCTCTGGAGGAGGAGGAGGAGGAGGAGGAGG	131
DB	67	GGGTGGAAGGAGGAGGAGATGACTGGAGTCTCTGGAGGAGGAGGAGGAGGAGGAGG	126
QY	132	AACCTTTCATTTTATGGAAGTGGTGGGATCAGGAGCTTCTCAGAGAGTTTCTCGTGGA	191
DB	127	AACCTTTCATTTTATGGAAGTGGTGGGATCAGGAGCTTCTCAGAGAGTTTCTCGTGGA	186
QY	192	CCAGAGCTGCTGCGAGGAGTCTCTGCTGAGTGATCAGAGCTGAGAGCTGCTGCG	251
DB	187	CCAGAGCTGCTGCGAGGAGTCTCTGCTGAGTGATCAGAGCTGAGAGCTGCTGCG	246
QY	252	GGACAGCAGCTGCGAGGAGTCTGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAG	311
DB	247	GGACAGCAGCTGCGAGGAGTCTGCTGTTGAGGAGGAGGAGGAGGAGGAGGAGGAG	306

RESULT 2
 ID AA160703 standard; CDNA; 1956 BP.
 XX
 AC AA160703;
 XX
 DT 22-OCT-2001 (first entry)
 XX
 DE Human polynucleotide SEQ ID NO 4692.
 XX
 KW Human: neurotropic; immunosuppressant; cytostatic; gene therapy; cancer;
 KW peripheral nervous system; neuropathy; central nervous system; CNS;
 KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
 KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
 KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
 KW leukaemia; ss.
 XX

